Filter posts

WSJ Article Cherry Picks Cost, Ignores Value of Medicines

Today’s Wall Street Journal story, “Price Increases Drive Drug Firms’ Revenue” reaffirms that old chestnut, …

Dr. Scott Gottlieb: A Clintonian Misdirection on Drug Prices

Today’s Wall Street Journal contains an excellent op-ed by Dr. Scott Gottlieb, a physician and …

Ezekiel Emanuel's Flawed Solution

In a New York Times op-ed today, Dr. Ezekiel Emanuel proposes “The Solution to Drug …

Send us Your BIO 2016 Session and Speaker Ideas

Even though BIO 2015 in Philadelphia was just two months ago, we already are hard …

When The Deck is Stacked Against Innovators, Everyone Loses

Yesterday, I took part in a series of successful meetings on Capitol Hill regarding the …

Unleashing the Full Promise of Biotechnology Innovation

Last week, I attended the announcement of President Obama’s Precision Medicine Initiative at the White …

Updated Legal and Regulatory Frameworks Needed for Biosimilars

Biosimilars raise novel and complex questions of science and law that require updated legal and …

Attacks on Venture Philanthropy Miss Mark Badly

In a highly problematic op-ed in today’s New York Times, freelance journalist Llewellyn Hinkes-Jones attacked venture philanthropy …

Wall Street Journal Highlights Promising Gene Therapy Advances

Yesterday, bluebird bio reported some very uplifting news at the annual meeting of the American …

San Francisco Chronicle: High Drug Co-Pays Deny Needed Treatments

Today, the San Francisco Chronicle published an op-ed that I wrote on the importance of …